CSPC PHARMA

1093
8.1000.87% ( +0.070 )
Delay Closed: Nov 16, 16:08:11

Overview

CSPC PHARMA (1093)

CSPC Pharmaceutical Group Limited, an investment holding company, engages in the manufacture and sale of pharmaceutical products in Mainland China, other Asian...

Open
8.065
High
8.165
Low
7.900
Prev. Close
8.030
Volume
103.09M
Turnover
829.59M
Avg Price
8.047
Bid/Ask Ratio
-96.70%
Amplitude
3.30%
52wk High
10.630
Volume Ratio
1.07
Turnover Ratio
0.89%
52wk Low
6.200
HK Mkt Cap
93.33B
Market CapHKD
93.33B
P/ETTM
10.91
P/EDynamic
6.65
P/EStatic
--
EPSTTM
0.742
EPSDynamic
1.22
EPSStatic
--
BVPS
3.76
P/B
2.15
HK Shares
11.52B
Dividend YieldTTM
4.07%
DividendTTM
0.33
Shares
11.52B
Min lot size
2,000
Currency
HKD

CSPC PHARMA Analyst Rating

View more

Forecast & Rating

Nov 13, 2026
Price forecast
HK$12.6756.45%
Forecast & RatingBuy
24analysts
  • Strong buy70.83%
  • Buy16.67%
  • Hold4.17%
  • Sell4.17%
  • Strong sell4.17%

Daily Events

  1. Nov, 16

    CSPC Pharma edged up 0.87% to HK$8.10 today as a modest rebound following recent profit-taking after pipeline catalyst announcements and cautious market sentiment. Intraday swung from HK$7.91 to HK$8.15 (3.04% range), but trading remained light with 0.89% turnover, indicating limited investor participation. Q2 earnings surprised on the upside with revenue at HK$14.01 billion (+104% YoY) and net income HK$6.05 billion (+416% YoY) posting 43.16% net margin, though Q1 sequential figures (HK$7.35B revenue, HK$977M net income) showed significant pullback. The company maintains an active clinical pipeline with multiple Phase I/II trials recently initiated, earning endorsement from Citi and CLSA. Valuation appears reasonable at 10.91 P/E and 2.15 P/B; stock trades 26% below 52-week high of HK$10.96 and down 4.48% YTD. However, the sharp Q1 sequential decline and current price positioning relative to 60-day average suggest lingering investor caution on earnings sustainability.

  2. Nov, 13

    CSPC Pharmaceutical declined 4.35% to HKD 8.03 today, primarily driven by profit-taking following the prior week's strong rally of 7.03%, with the stock falling from its morning high of HKD 8.275 to close near session lows. Fundamentals remain supportive: Q2 net profit surged to HKD 60.5 billion, up 415% year-over-year, with net margin of 43.16% and EPS of HKD 0.5286. The clinical pipeline is advancing steadily with SYS6090 for liver cancer achieving a 40% response rate, alongside Phase I/II programs including SYS6062 for advanced solid tumors and SYS6057 RSV vaccine candidate. Valuation-wise, the stock trades 26.73% below its 52-week high of HKD 10.96, below its 20-day moving average of HKD 8.32, at a PE multiple of 10.82. Down 5.31% year-to-date, the pullback reflects broader healthcare sector headwinds, though the robust pipeline remains a key structural support.

  3. Nov, 12

    CSPC Pharma declined about 1.4% today amid profit-taking pressures and broader market weakness. Following a 7% weekly gain driven by accelerating pipeline initiations, market participants are now digesting the company's strong earnings. Q2 revenue of HK$14.01 billion nearly doubled year-over-year with 104% growth, while net profit surged 416% to HK$6.046 billion and EPS reached HK$0.5286, delivering an impressive ROE of 59%. However, Q1's 38% YoY EPS decline also signals earnings base volatility. From valuation and price positioning perspectives, the P/E of 11.31 appears reasonable. The stock is essentially flat year-to-date, trades about 23% below the 52-week high of HK$10.96, and currently sits roughly 7% below the 60-day moving average of HK$9.006.

  4. Nov, 11

    CSPC Pharmaceutical declined 1.1% to HK$8.53 today, primarily driven by profit-taking following recent sharp gains. The company's Q2 results were robust, with revenue surging 104.28% year-over-year to HK$14.0 billion and net profit jumping 415.72% to HK$6.0 billion, achieving a net margin of 43.16%. The company continues advancing its R&D pipeline, initiating multiple clinical trials including SYS6055 for non-Hodgkin lymphoma and other oncology candidates, demonstrating strong product momentum. Valuation-wise, the stock trades at just 11.49x P/E and sits 22.17% below its 52-week high of HK$10.96, suggesting upside potential. Market sentiment remains constructive, with Citi and CLSA viewing recent weakness in China healthcare stocks as a buying opportunity, while the company is slated to announce nine-month results which could serve as a near-term catalyst.

  5. Nov, 9

    CSPC Pharmaceutical closed at HK$8.43, down 0.24% from the previous close of HK$8.45, after retreating from an intraday high of HK$8.60. This pullback appears driven by profit-taking following last week's strong 7.03% rally, compounded by broad weakness in Hong Kong's benchmark index today. The company's latest Q2 results demonstrated robust profitability: operating revenue reached HK$14.1 billion (+104% YoY), net profit surged to HK$6.05 billion (+416% YoY), and net margin expanded to 43.2%, delivering EPS of HK$0.5286. The R&D pipeline remains active with multiple clinical trials underway. Valuation metrics appear attractive at a P/E of 11.4x; the stock trades near its 20-day moving average but remains notably below the 60-day average (8.43 vs 9.02), down over 23% from the 52-week high of HK$10.96. However, Q2's stellar earnings largely reflect recovery from Q1's weak base—the prior quarter saw flat revenue and a 38% profit decline, signaling notable earnings volatility.

News

Bullish vs. Bearish — Last 3 Months

11.7k followers · 0 opinions
▲Bullish50%
50%Bearish▼